Potential link between HMGCoA reductase inhibitor (statin) use and interstitial lung disease

Medical Journal of Australia

Volumn 187, Issue 4, 2007, Pages 253-

  Golomb, Beatrice A ^a   Evans, Marcella A ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ENZYME INHIBITOR;

CLINICAL FEATURE; CLINICAL OBSERVATION; DRUG INDUCED DISEASE; DRUG POTENTIATION; HUMAN; INTERSTITIAL LUNG DISEASE; LETTER; LUNG BIOPSY; MITOCHONDRIAL ENCEPHALOMYOPATHY; MITOCHONDRIAL TOXICITY; CHEMICALLY INDUCED DISORDER; DRUG COMBINATION; NOTE;

AMIODARONE; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LUNG DISEASES, INTERSTITIAL;

EID: 34848878690     PISSN: 0025729X     EISSN: 13265377     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2007.tb01223.x     Document Type: Letter

References (5)

1. Walker T, McCaffery J, Steinfort C. Potential link between HMG-CoA reductase inhibitor (statin) use and interstitial lung disease. Med J Aust 2007; 186: 91-94.
2. Bolt MW, Card JW, Racz WJ, et al. Disruption of mitochondrial function and cellular ATP levels by amiodarone and N-desethylamiodarone in initiation of amiodarone-induced pulmonary cytotoxicity. J Pharmacol Exp Ther 2001; 298: 1280-1289.
3. Phillips PS, Haas RH, Bannykh S, et al. Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med 2002; 137: 581-585.
4. Alsheikh-Ali AA, Karas RH. Adverse events with concomitant amiodarone and statin therapy. Prev Cardiol 2005; 8: 95-97.
5. Fadic R, Johns DR. Clinical spectrum of mitochondrial diseases. Semin Neurol 1996; 16: 11-20.